<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6B1116F7-2B90-48CE-91E3-636259C212FE"><gtr:id>6B1116F7-2B90-48CE-91E3-636259C212FE</gtr:id><gtr:name>EDAP TMS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/74C9BE1A-DF07-4388-B5F3-BEE269771544"><gtr:id>74C9BE1A-DF07-4388-B5F3-BEE269771544</gtr:id><gtr:name>Royal Institution of Great Britain</gtr:name><gtr:address><gtr:line1>The Royal Institution</gtr:line1><gtr:line2>21 Albemarle Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>W1S 4BS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6BA7540-D352-4E45-9037-F821CB3EB0C8"><gtr:id>C6BA7540-D352-4E45-9037-F821CB3EB0C8</gtr:id><gtr:name>Advanced Medical Diagnostics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6B1116F7-2B90-48CE-91E3-636259C212FE"><gtr:id>6B1116F7-2B90-48CE-91E3-636259C212FE</gtr:id><gtr:name>EDAP TMS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74C9BE1A-DF07-4388-B5F3-BEE269771544"><gtr:id>74C9BE1A-DF07-4388-B5F3-BEE269771544</gtr:id><gtr:name>Royal Institution of Great Britain</gtr:name><gtr:address><gtr:line1>The Royal Institution</gtr:line1><gtr:line2>21 Albemarle Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>W1S 4BS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6BA7540-D352-4E45-9037-F821CB3EB0C8"><gtr:id>C6BA7540-D352-4E45-9037-F821CB3EB0C8</gtr:id><gtr:name>Advanced Medical Diagnostics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/65F45FC6-F48C-49E6-B36C-A7F2A6CAA71A"><gtr:id>65F45FC6-F48C-49E6-B36C-A7F2A6CAA71A</gtr:id><gtr:firstName>Hashim</gtr:firstName><gtr:otherNames>Uddin</gtr:otherNames><gtr:surname>Ahmed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002509"><gtr:id>046D7CDD-2CD5-4FA0-A5F7-01E45E96883E</gtr:id><gtr:title>Improving the Diagnosis and Treatment of Localised Prostate Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002509</gtr:grantReference><gtr:abstractText>The way we diagnose prostate cancer at the moment is flawed. At present, a blood test called the prostate specific antigen, or PSA, is used to decide who gets a prostate biopsy. Prostate biopsy is painful, causes bleeding and sometimes serious infections. It often detects harmless cancers that need no treatment and misses important cancers that do. This is because prostate biopsies are random - we cannot see the cancer so needles are fired into the prostate in the hope that we will hit the cancer. 

Once diagnosed, the way we treat early prostate cancer can cause a lot of harm. Current treatments for early prostate cancer target the whole prostate, causing damage to surrounding structures. This can lead to urine leak, poor erections and back passage problems.

The research

I will test the ability of several markers in blood and urine as well as imaging to accurately predict the presence or absence of important prostate cancer. 

I will also test whether treating the cancer only, in order to avoid damaging surrounding structures, is effective in cancer control and whether the harms of whole-gland treatments can be reduced.

The possible benefits

Reduce the number of men who undergo unnecessary prostate biopsy
Reduce the risk of being diagnosed with a harmless prostate cancer
Improve the diagnosis of prostate cancer that is important
Reduce the harms of treatment</gtr:abstractText><gtr:technicalSummary>To improve the diagnosis and treatment pathways in prostate cancer so that fewer and better biopsies are taken with fewer and better treatments conducted.

Objectives

A. To evaluate the ability of novel tissue and imaging biomarkers to detect and rule-out clinically significant prostate cancer (fewer and better biopsies, fewer treatments)
B. To evaluate the genito-urinary, bowel, quality of life and cancer control outcomes after a issue-preserving strategy that targets only the area of prostate cancer (better treatments)

Design and Methodology

The two objectives will be evaluated in the following way:

A. Fewer and better biopsies, fewer treatments

1. Collect and store tissue samples and imaging data-files from men prior to biopsy 
2. Validate known diagnostic tests in detecting and ruling-out clinically significant prostate cancer,
 a) tissue biomarkers: urinary MSMB, serum kallikreins and PTEN-associated glycoproteins
 b) imaging datafiles: diffusion-weighted and dynamic contrast enhanced MRI quantitative parameters and ultrasound tissue characterisation algorithms
3. Conduct a discrete choice experiment to evaluate men?s preferences for, and trade-offs between, the attributes of different diagnostic strategies and tests

B. Better treatment

1. Conduct a phase II multicentre trial to evaluate the,
 a) precision and reproducibility of genitourinary, rectal and health-related quality of life outcomes 
 b) medium-term histological outcomes of treated and untreated prostate tissue
 c) clinical validity of tissue and imaging biomarkers in detection of local failure after focal therapy
2. Develop a predictive model, using tissue and imaging biomarkers to predict outcomes after focal therapy 
3. Conduct a formal consensus panel meeting of international experts to discuss and develop a pragmatic randomised controlled trial protocol comparing focal therapy to standard of care

Scientific and Medical Opportunities

A. Fewer and better bisies, fewer treatments

1. A risk calculator that may identify men who require a biopsy so that detection of clinically significant disease is improved and men with insignificant disease can avoid an unnecessary biopsy and treatment
2. A unique collection of blood and urine samples and imaging datafiles, linked to template mapping biopsy findings, that can be used to test future promising biomarkers of prostate cancer

Better treatment

1. The development of a pragmatic phase III randomised controlled trial protocol to evaluate the long term outcomes of focal therapy compared to standard of care
2. A unique collection of pre- and post-treatment pathological samples from men in whom the dominant or index lesion has been ablated and all other cancer foci remain in-situ.</gtr:technicalSummary><gtr:fund><gtr:end>2016-10-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1226741</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>Prostate MR Imaging Study</gtr:description><gtr:id>15F120A3-9118-4C0E-A7F5-F6B2C95F89A0</gtr:id><gtr:impact>NIHR HTA grant (&amp;pound;3.2Million) 2010-2015

Multidisciplinary between between Computer Science, Radiology, Oncology, Urology and MRC Clinical Trials Unit</gtr:impact><gtr:outcomeId>XLmQp69MezM-1</gtr:outcomeId><gtr:partnerContribution>Clinical Trial design and management of PROMISMethodological input to trial
Translational elements of PROMIS</gtr:partnerContribution><gtr:piContribution>Lead PI for collaboration</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Institution of Great Britain</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Magnetic nanoparticle therapy for prostate cancer</gtr:description><gtr:id>5E03822C-FD94-4B99-972D-7453DB997909</gtr:id><gtr:impact>Grant success</gtr:impact><gtr:outcomeId>GWYBFJb1Qe4-1</gtr:outcomeId><gtr:partnerContribution>NIHR i4i grant success in developing new therapy</gtr:partnerContribution><gtr:piContribution>Lead applicant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Intratumour heterogeneity in prostate cancer</gtr:description><gtr:id>88F19C45-8B45-4254-9801-3CE2755E9C1F</gtr:id><gtr:impact>US PCF grant</gtr:impact><gtr:outcomeId>SaxAHZn4Yrb-1</gtr:outcomeId><gtr:partnerContribution>Clinical Lead applicant for project</gtr:partnerContribution><gtr:piContribution>Co-applicant on grant from Prostate Cancer Foundation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>Intratumour heterogeneity in prostate cancer</gtr:description><gtr:id>462DF1F9-973A-4FBD-890D-066EAE88BEAE</gtr:id><gtr:impact>US PCF grant</gtr:impact><gtr:outcomeId>SaxAHZn4Yrb-2</gtr:outcomeId><gtr:partnerContribution>Clinical Lead applicant for project</gtr:partnerContribution><gtr:piContribution>Co-applicant on grant from Prostate Cancer Foundation</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Medical Image Computing</gtr:department><gtr:description>SmartTarget</gtr:description><gtr:id>B130B941-20F5-4B49-A5EA-AA8FFB5B66FC</gtr:id><gtr:impact>Urological Surgery
Clinical Trials
Health Economics and Health Services Research
Computer and Engineering Science</gtr:impact><gtr:outcomeId>EVARKRW7ev5-2</gtr:outcomeId><gtr:partnerContribution>Collaborative application to Wellcome Trust/DoH HICF SmartSurgery call</gtr:partnerContribution><gtr:piContribution>Co-applicant (co-Lead on clinical)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Lille (INSERM)</gtr:department><gtr:description>FP7 Erasmus Medical Centre</gtr:description><gtr:id>EE545424-A239-4B66-AB3E-B6E401ADDAA4</gtr:id><gtr:impact>Consortium involving Lille Universty Hospital, INSERM-Lille (France), Uppsala (Sweden), and Erasmus University Medical Centre.</gtr:impact><gtr:outcomeId>B16004D48CF-3</gtr:outcomeId><gtr:partnerContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010EU FP7 Partner (shortlisted)EU FP7 Consortium partnerEU FP7 Consortium industrial partnerEU FP7 Industrial partner</gtr:partnerContribution><gtr:piContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Medical Image Computing</gtr:department><gtr:description>Focal Salvage Trial (NCRN FORECAST Trial)</gtr:description><gtr:id>CCACE806-D228-45E0-AAEF-0BC8BC99BA82</gtr:id><gtr:impact>Collaboration with imaging scientists, radiologists and pathologists for each aspect of the trial.</gtr:impact><gtr:outcomeId>Wgp6ze9dPWp-1</gtr:outcomeId><gtr:partnerContribution>The CMIC group are conducting image registration and image analysis of the imaging data collected</gtr:partnerContribution><gtr:piContribution>I am lead PI on the FORECAST trial. I have written the protocol and will be guarantor on its conduct and reporting.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prostate MR Imaging Study</gtr:description><gtr:id>37549041-B1D6-4823-8F83-185FC9473AE1</gtr:id><gtr:impact>NIHR HTA grant (&amp;pound;3.2Million) 2010-2015

Multidisciplinary between between Computer Science, Radiology, Oncology, Urology and MRC Clinical Trials Unit</gtr:impact><gtr:outcomeId>XLmQp69MezM-2</gtr:outcomeId><gtr:partnerContribution>Clinical Trial design and management of PROMISMethodological input to trial
Translational elements of PROMIS</gtr:partnerContribution><gtr:piContribution>Lead PI for collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>FP7 Erasmus Medical Centre</gtr:description><gtr:id>DAAAA2DB-8E56-4111-9A50-B9F099C796BD</gtr:id><gtr:impact>Consortium involving Lille Universty Hospital, INSERM-Lille (France), Uppsala (Sweden), and Erasmus University Medical Centre.</gtr:impact><gtr:outcomeId>B16004D48CF-1</gtr:outcomeId><gtr:partnerContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010EU FP7 Partner (shortlisted)EU FP7 Consortium partnerEU FP7 Consortium industrial partnerEU FP7 Industrial partner</gtr:partnerContribution><gtr:piContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SmartTarget</gtr:description><gtr:id>E63DF5EA-084F-42D7-AA2F-6AF57C9CAC05</gtr:id><gtr:impact>Urological Surgery
Clinical Trials
Health Economics and Health Services Research
Computer and Engineering Science</gtr:impact><gtr:outcomeId>EVARKRW7ev5-1</gtr:outcomeId><gtr:partnerContribution>Collaborative application to Wellcome Trust/DoH HICF SmartSurgery call</gtr:partnerContribution><gtr:piContribution>Co-applicant (co-Lead on clinical)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Comprehensive Clinical Trials Unit</gtr:department><gtr:description>SmartTarget</gtr:description><gtr:id>F6EDD784-F39B-4FF7-8895-30C5211F6AA2</gtr:id><gtr:impact>Urological Surgery
Clinical Trials
Health Economics and Health Services Research
Computer and Engineering Science</gtr:impact><gtr:outcomeId>EVARKRW7ev5-3</gtr:outcomeId><gtr:partnerContribution>Collaborative application to Wellcome Trust/DoH HICF SmartSurgery call</gtr:partnerContribution><gtr:piContribution>Co-applicant (co-Lead on clinical)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Intratumour heterogeneity in prostate cancer</gtr:description><gtr:id>D87E03D6-8AD1-4521-AE19-ADCF53C833F0</gtr:id><gtr:impact>US PCF grant</gtr:impact><gtr:outcomeId>SaxAHZn4Yrb-3</gtr:outcomeId><gtr:partnerContribution>Clinical Lead applicant for project</gtr:partnerContribution><gtr:piContribution>Co-applicant on grant from Prostate Cancer Foundation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Medical Image Computing</gtr:department><gtr:description>Image registration</gtr:description><gtr:id>BAE7F640-2901-4356-991C-7C36DC89173F</gtr:id><gtr:impact>Successful HTA NIHR project (&amp;pound;2M) (Ahmed is coordinator and co-PI) Shortlisted for MRC DPFS (Ahmed is co-applicant) (&amp;pound;0.5M) Shortlisted for EU FP7 Health programme (Ahmed is coapplicant and coordinator) NIHR Comprehensive Biomedical Research centre grant (&amp;pound;100,000) (Co-applicant)</gtr:impact><gtr:outcomeId>98CA7D51405-1</gtr:outcomeId><gtr:partnerContribution>Data collection of MRI scans and ultrasound 3D data for registration and fusion. EU FP7 application for Focal Therapy mutlicentre European trial (shortlisted) HTA MRI Prostate Study (successful) (&amp;pound;2M)</gtr:partnerContribution><gtr:piContribution>Clinical data and image data for registration modelling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>FP7 Erasmus Medical Centre</gtr:description><gtr:id>C1D77324-87BB-4F26-93BE-62CDB23C200C</gtr:id><gtr:impact>Consortium involving Lille Universty Hospital, INSERM-Lille (France), Uppsala (Sweden), and Erasmus University Medical Centre.</gtr:impact><gtr:outcomeId>B16004D48CF-2</gtr:outcomeId><gtr:partnerContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010EU FP7 Partner (shortlisted)EU FP7 Consortium partnerEU FP7 Consortium industrial partnerEU FP7 Industrial partner</gtr:partnerContribution><gtr:piContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EDAP TMS</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>FP7 Erasmus Medical Centre</gtr:description><gtr:id>BE93459F-7A62-4D76-B9E7-A9FCB62A86DC</gtr:id><gtr:impact>Consortium involving Lille Universty Hospital, INSERM-Lille (France), Uppsala (Sweden), and Erasmus University Medical Centre.</gtr:impact><gtr:outcomeId>B16004D48CF-5</gtr:outcomeId><gtr:partnerContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010EU FP7 Partner (shortlisted)EU FP7 Consortium partnerEU FP7 Consortium industrial partnerEU FP7 Industrial partner</gtr:partnerContribution><gtr:piContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advanced Medical Diagnostics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>FP7 Erasmus Medical Centre</gtr:description><gtr:id>260E14E5-053E-48A0-9E5D-7AB1C2B961C4</gtr:id><gtr:impact>Consortium involving Lille Universty Hospital, INSERM-Lille (France), Uppsala (Sweden), and Erasmus University Medical Centre.</gtr:impact><gtr:outcomeId>B16004D48CF-4</gtr:outcomeId><gtr:partnerContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010EU FP7 Partner (shortlisted)EU FP7 Consortium partnerEU FP7 Consortium industrial partnerEU FP7 Industrial partner</gtr:partnerContribution><gtr:piContribution>EU FP7 Application for Euro 6Million consortium shortlisted. Ahmed and Emberton at UCL are coordinators (Focal therapy in Prostate Cancer project). Decision due March 2010</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Focal Therapy trial results</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F614B71F-2AD5-4F73-8BEE-42148106C7E8</gtr:id><gtr:impact>All terristorial news channels (BBC, Channel 4, ITN, Channel 5), multiple international news channels, multiple radio (national and International), 4 national UK newspapers and one front page (Telegraph) covered this story in April 2012. Press release via MRC Press Office

International recognition of MRC funded trial in novel focal therapy of prostate cancer</gtr:impact><gtr:outcomeId>ganKRT6TXnr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual National Meeting of the Prostate Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E7F8DC7-9F7F-432D-A84D-AC6C2638164E</gtr:id><gtr:impact>Lecture on 'The role of focal therapy in prostate cancer.'

Increased awareness and recruitment to trials</gtr:impact><gtr:outcomeId>661D2A0DA92</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Norfolk and Norwich Prostate Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CD3461F2-9547-479B-9E5E-AC4CFFF47429</gtr:id><gtr:impact>Lecture on 'Prostate cancer management: minimally invasive treatments.'

Increased recruitment to trials run under MRC funding</gtr:impact><gtr:outcomeId>E013067321B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Tour d'Europe</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3672A9DC-FC87-4B57-8E52-C0B5C11733D7</gtr:id><gtr:impact>200 oncologists and urologists from Europe attended this event

None</gtr:impact><gtr:outcomeId>NPNi3qiNVvP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'My Man' campaign (Prostate Cancer Research Centre charity).</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D5CB9FBC-9DA0-4428-A53E-157C24ADC12A</gtr:id><gtr:impact>Radio Interviews: 'My Man' campaign (Prostate Cancer Research Centre charity). 13 local radio stations including 10 independent and 3 BBC.

Increased awareness and recrutment to trials.</gtr:impact><gtr:outcomeId>55D0954BD79</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Foreign Press Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9538014-D3FA-4D82-8132-CEE23FA278F7</gtr:id><gtr:impact>Prsentation on focal theapy in prostate to Foreign Press rganisation of 15 journalists from around the world

Newspaper publicity on research</gtr:impact><gtr:outcomeId>DA869BBC7D1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper interviews</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBC59899-EE11-41A3-AB1F-6D73D98507A9</gtr:id><gtr:impact>Newspaper interviews in relation to article: HIFU in the management of prostate cancer - the first UK results. Daily Telegraph, Daily Mail, The Times, Daily Express, BBC Website.

Increased recruitment to trials</gtr:impact><gtr:outcomeId>3EA0AED58E9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multi-parametric ultrasound in the detection of clinically significant prostate cancer</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG13-025</gtr:fundingRef><gtr:id>47F88CB7-17B1-406E-8D90-2A7F59921828</gtr:id><gtr:outcomeId>54647ccae91654.48319103</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>i4i</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>04D84996-5D38-486B-ACD4-893723AAB5E0</gtr:id><gtr:outcomeId>bctLKCDsXbL</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>195000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROMIS-T Biobank</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>51DC4170-A843-47BD-B803-967C560FF87C</gtr:id><gtr:outcomeId>bJ4kvBBFCzx0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Pelican Cancer Foundation</gtr:fundingOrg><gtr:id>9BF31555-E99A-4ED2-A94A-9925B3C1225F</gtr:id><gtr:outcomeId>gniDZ2YSkXA</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer Research Foundation</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>EB7DEEC0-604B-4780-A51A-8EC8D6D4EC58</gtr:id><gtr:outcomeId>F7F4BDFFC3E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR i4i Invention for Innovation (i4i) Programme</gtr:department><gtr:description>i4i</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8DA66344-980C-4598-8FD6-780878827FF5</gtr:id><gtr:outcomeId>41D11DFF9490</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>St Peters Trust</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>St Peter's Trust for Kidney, Bladder and Prostate Research</gtr:fundingOrg><gtr:id>CAD62C6E-813A-4F06-9400-5E11F3694ECA</gtr:id><gtr:outcomeId>0F61ED9581F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>St Peters Trust</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>St Peter's Trust for Kidney, Bladder and Prostate Research</gtr:fundingOrg><gtr:id>72426622-B1BA-4AF9-82A1-1B7227332740</gtr:id><gtr:outcomeId>5737676A1940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Imaging in Prosate Cancer</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>E8A7517A-9900-4E9F-92EB-FE5F5C5C0E7F</gtr:id><gtr:outcomeId>bsVFFQJi6qV0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate UK</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>8F3DFDDB-468E-4803-87AB-76F9EA577F3F</gtr:id><gtr:outcomeId>4E26286C5070</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Challenge Award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Prostate Cancer Foundation</gtr:fundingOrg><gtr:id>5FC957AD-7757-4471-89E1-235EDF9C5871</gtr:id><gtr:outcomeId>PKtz74bxhcD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>320000</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Radiofrequency ablation for treatment of prostate cancer</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Trod Medical</gtr:fundingOrg><gtr:id>C1A146A9-0E72-490D-AD48-00E75BC9B052</gtr:id><gtr:outcomeId>54647c72058da2.29797272</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>191000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>UCH/UCL NIHR CBRC</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>54D8FB23-3F32-4725-82AA-85E5B4B0A635</gtr:id><gtr:outcomeId>CC6B78F2B2A0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2038776</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Senior Research Fellowship</gtr:department><gtr:description>Wellcome Trust Senior Clinical Fellowship</gtr:description><gtr:end>2022-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F80EED94-2D87-43F5-8964-0668259868F7</gtr:id><gtr:outcomeId>5915ddb00b8221.86710971</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Smart Surgery</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>71097FE2-76F5-431A-816E-045CFBBB2F95</gtr:id><gtr:outcomeId>a8r7C9BAsiu</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>285845</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer UK Project grant</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG13-026</gtr:fundingRef><gtr:id>FCA3CD43-C9B9-4AE9-BBC6-EEAD56450E35</gtr:id><gtr:outcomeId>jDj3kbptLZi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRX302 in the focal treatment of prostate cancer</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Sophiris Bio</gtr:fundingOrg><gtr:id>7EEE9F4A-3231-47BA-A1A7-C3B86EC295AB</gtr:id><gtr:outcomeId>54647d14151c97.16279944</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tissue Type Imaging for Prostate Cancer</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>C1658614-B905-497C-A320-580E8AAD06AC</gtr:id><gtr:outcomeId>HokuUWSK2gd0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>HTA Diagnostic Call</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>BFE52567-EBA9-4103-A574-C82CD13D9A96</gtr:id><gtr:outcomeId>387AFA036C40</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Image Registration for Prostate Cancer TRUS biopsy</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>CBC3A483-2696-44C7-A0FA-BDE4713E68D5</gtr:id><gtr:outcomeId>KLTCY3SUgDm0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinician Scientist</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FBB07C9D-0F16-4685-9B84-B13223875DA2</gtr:id><gtr:outcomeId>nAaTXWbfru70</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Electroporation for Focal Therapy of Prostate Cancer</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>2B342928-D8B0-415D-B78E-9FDB3174A37B</gtr:id><gtr:outcomeId>SekkfxxYPic0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation within the EAU prostate cancer guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>GUIDELINE ON PROSTATE CANCER 2012</gtr:guidelineTitle><gtr:id>51484CA7-A71C-4552-9D3E-BAEC28BAB480</gtr:id><gtr:impact>The EAU guidelines are followed around Europe and internationally in the USA, Japan, Australia/NZ so have major impact. They cite focal therapy and my work and as a result numerous centres have started focal therapy programmes allowing greater access to the treatment.</gtr:impact><gtr:outcomeId>TNLDpg3fCEv</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Focal therapy in prostate cancer</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A96F39D2-C287-4E4D-9531-915C0E1949B1</gtr:id><gtr:impact>Multiple international centres have started focal therapy in prostate cancer clinical programmes as a result of our trial results published and covered in international publicity in April 2012</gtr:impact><gtr:outcomeId>TX3EspYx1ZC</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRI prior to prostate biopsy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F4A9F409-E1EE-4607-805E-C64F4FD271ED</gtr:id><gtr:impact>Multiple sites around the world have sarted MRI programmes to diagnose prostate cancer as a result of this work which was widely publicised and published/presented at international conferences.</gtr:impact><gtr:outcomeId>apgDW9rEvbw</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Focal HIFU guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Focal therapy using high-intensity focused ultrasound (HIFU) for localised prostate cancer (IPG424)</gtr:guidelineTitle><gtr:id>6C72DB24-1711-40EB-B828-F0BB0747D445</gtr:id><gtr:impact>The NICE guidance allows physicians to use Focal HIFU within a registry or trials. As a result, about 10-15 surgeons in the UK have started focal therapy programmes in the UK</gtr:impact><gtr:outcomeId>EGCPyPRDr2e</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Multifunctional MRI in detection of prostate cancer is used in the MRC funded trials to localise disease for focal therapy. This phase II data has shown good accuracy for localisation of disease and has now been progressed to a large scae study as a result.</gtr:description><gtr:id>C9DA382C-0F82-4B59-B324-5B5D7D780853</gtr:id><gtr:impact>NIHR HTA Trial (Ahmed and Emberton lead PIs) awarded (&amp;pound;2M) to validate multifunctional MRI</gtr:impact><gtr:outcomeId>875EA8E2915</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Multifunctional MRI in detection of prostate cancer</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Phase II Fcal therapy Hemiablation HIFU NCRI Trial completed (in publication stage).</gtr:description><gtr:id>FE7F0643-C976-4F22-96A1-2CD51ED7EE9A</gtr:id><gtr:impact>Shortlisted for multicente phase II EU FP7 Focal Therapy HIFU trial</gtr:impact><gtr:outcomeId>3F6704C06C6</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Focal Therapy</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Nuada Medical</gtr:companyName><gtr:description>As a result of this work they now offer private MRIs and mapping biopsies pioneered in this work prior to prostate biopsy and have set up a dedicated MRI scanner on Harley Street.
This type of practice is now being duplicated across a number of other private hospitals</gtr:description><gtr:id>6F978C6C-BFD0-464B-B90D-3988A71D59D1</gtr:id><gtr:impact>Change in private practice referral patterns around Harley Street</gtr:impact><gtr:outcomeId>cPtppTHpKJQ</gtr:outcomeId><gtr:url>http://www.nuadamedical.co.uk/nm-about.html</gtr:url><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>1EA58EED-8328-408C-BB2D-7549D6AD33D1</gtr:id><gtr:title>The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b63ab154847d2ecc74557feba2ee569d"><gtr:id>b63ab154847d2ecc74557feba2ee569d</gtr:id><gtr:otherNames>Grey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>5aa6688752e540.40805718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21C058FD-C380-41FF-BA38-02FB74DC6E6C</gtr:id><gtr:title>Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915db79492544.65510974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E2242E7-F5D8-4A26-A8C7-A1B31BE07E18</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>5915dadbe14054.00391766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ACE945A-398D-42E8-B6DD-27A7A83CF295</gtr:id><gtr:title>Will focal therapy become a standard of care for men with localized prostate cancer?</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1743-4254</gtr:issn><gtr:outcomeId>9745AE92C76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9EB141A-C21B-44B2-A801-423AE5C54E63</gtr:id><gtr:title>Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5915dc83c46218.49386958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4894171-B4FF-47A4-A0AC-CEA891ED7EAB</gtr:id><gtr:title>Characterizing clinically significant prostate cancer using template prostate mapping biopsy.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>okTKAt9Nj9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A264BC-A941-49A7-AEFF-B444FC6A05E6</gtr:id><gtr:title>Focal therapy for prostate cancer: rationale and treatment opportunities.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4bae62be7efeeedfdabbacb589902f"><gtr:id>ff4bae62be7efeeedfdabbacb589902f</gtr:id><gtr:otherNames>Kasivisvanathan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_16610_20_23759249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61BF3632-ADC2-438A-BE23-95B6257E605F</gtr:id><gtr:title>Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>54647b61bee5d6.88387424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A01F9F-54C2-41FD-AF05-66CF3B29FFF1</gtr:id><gtr:title>Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e4e9f25a190091ba3064749126611e"><gtr:id>52e4e9f25a190091ba3064749126611e</gtr:id><gtr:otherNames>Bass EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>5915dad769daa3.20194687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D328BE10-B27A-4E35-B380-5F7BA80AB559</gtr:id><gtr:title>Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2cd1838bc767b14b82f6cb0063c3da1"><gtr:id>d2cd1838bc767b14b82f6cb0063c3da1</gtr:id><gtr:otherNames>Jarow JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>5915db7a9baef8.07907786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8C1C963-5C8D-4460-9279-075748364E65</gtr:id><gtr:title>Modelling prostate motion for data fusion during image-guided interventions.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn><gtr:outcomeId>cm9SNbznkeF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74325D08-2B86-45FE-B733-1043DFFE94C0</gtr:id><gtr:title>A biomedical engineering approach to mitigate the errors of prostate biopsy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>pm_16610_20_22310216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D01EBE06-F760-4106-89ED-C5139CB9385F</gtr:id><gtr:title>The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>DJfnLTK92Zk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D41E793E-7F9A-405E-813B-60BAE6CFFFCF</gtr:id><gtr:title>Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of endourology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0892-7790</gtr:issn><gtr:outcomeId>pm_16610_20_22142404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE81B47D-6DF4-4DA5-8894-EA4601F72399</gtr:id><gtr:title>Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915dc85a7e843.23685994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D42B094F-1A34-4E7E-BDE6-919AD6A2E6EC</gtr:id><gtr:title>Benchmarks for success in focal therapy of prostate cancer: cure or control?</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>GbMEiWPS7C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4758C801-657C-46D3-A08E-91DDD31707D0</gtr:id><gtr:title>Focal therapy will become a standard option for selected men with localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>54647b63de02d7.06905740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0BEC825-96F2-4FAC-BF0A-4540560DAEF8</gtr:id><gtr:title>Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64c0843bb006800fb50dde3eef778617"><gtr:id>64c0843bb006800fb50dde3eef778617</gtr:id><gtr:otherNames>Brizmohun Appayya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>5aa6688720ee72.40422766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DAC7ECE-6278-4329-9708-A0811B2DEBAD</gtr:id><gtr:title>Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5915dc8430f472.01150893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06A0474F-65FC-489D-9746-F54334CC1702</gtr:id><gtr:title>High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>8A85A33F3BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E98367A-BA62-486F-9102-8FE15398E4B7</gtr:id><gtr:title>Is there a role for magnetic resonance imaging in diagnosing colovesical fistulas?</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723d430c163a2cdebe1f8605d582dd4d"><gtr:id>723d430c163a2cdebe1f8605d582dd4d</gtr:id><gtr:otherNames>Ravichandran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>AEE42055333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14BC1913-6F2D-4344-BB01-31E09F0DEA73</gtr:id><gtr:title>Prostate cancer: Time for active surveillance of intermediate-risk disease?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>pm_16610_20_23147924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2B17BFD-02D8-431D-9024-9177A68ACA93</gtr:id><gtr:title>F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>AJR. American journal of roentgenology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ded67235e4b1f2e87e50805699e080"><gtr:id>28ded67235e4b1f2e87e50805699e080</gtr:id><gtr:otherNames>Haroon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0361-803X</gtr:issn><gtr:outcomeId>5915dadb3db789.53912751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB1CA72F-FD23-4D03-A61C-5F64A9D459FF</gtr:id><gtr:title>The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b97b4073d9043a8367a2cc592eb5578"><gtr:id>0b97b4073d9043a8367a2cc592eb5578</gtr:id><gtr:otherNames>Abd-Alazeez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>pm_16610_20_24055430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>743C9EBD-1794-4D12-A81A-1BF54C5851E2</gtr:id><gtr:title>Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_16610_20_22512844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53A7E067-E6B6-4ED6-A4C5-3D108DA51AC7</gtr:id><gtr:title>Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>D9AC3D02BCC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6A50796-AF12-48D6-ADF7-1626FBE51D21</gtr:id><gtr:title>Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>pm_16610_20_23627000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C155E5-8920-4A1F-A170-4E2B90BA6837</gtr:id><gtr:title>A core outcome set for localised prostate cancer effectiveness trials.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef10e2fc0d09f68bd9fed1aa09dc9d09"><gtr:id>ef10e2fc0d09f68bd9fed1aa09dc9d09</gtr:id><gtr:otherNames>MacLennan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5915dad8a852e8.94275612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4963BD10-9767-47CD-8C2C-2D54E7E49DDA</gtr:id><gtr:title>Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5915dad9a56952.30437741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>375884B4-497C-407B-8675-7EE77D3FF54A</gtr:id><gtr:title>Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>5915dadaa59ec5.39495120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F636573B-F833-4513-B220-EEC4056B0D62</gtr:id><gtr:title>Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>pm_16610_20_22566285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>463C01BD-0729-429A-9C4C-0239F553145D</gtr:id><gtr:title>Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>pm_16610_20_22907704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C75CF63-5A07-4832-B045-DDCCA2EA7D24</gtr:id><gtr:title>The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0953d8a49279c0166f606bce7c66b82"><gtr:id>c0953d8a49279c0166f606bce7c66b82</gtr:id><gtr:otherNames>Moore CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>5915dad9d8ed89.28129136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>099D538C-1F93-48AB-B36C-3799A5612DC7</gtr:id><gtr:title>PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>5915dadc2f4f69.69059460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7FD450C-AE6D-45E6-A372-03AA3BDCCD77</gtr:id><gtr:title>The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ad2d3be338e61118503281999024b4"><gtr:id>40ad2d3be338e61118503281999024b4</gtr:id><gtr:otherNames>Yap T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915dc82d60093.06423680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E526B20B-65EF-4EFF-9630-851C594D18F4</gtr:id><gtr:title>An update on the management of Wilms' tumour.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>396A7307CDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>595CC197-76D3-4F0D-8505-D5B936EEFCF4</gtr:id><gtr:title>Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>hpwCK4Xop5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDBA7C2E-8277-4026-983B-4D3D17490C2D</gtr:id><gtr:title>Can we deliver randomized trials of focal therapy in prostate cancer?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>54647b62a1e673.89355133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3815FFCB-927F-44C7-BF9F-57D2C9DF4F64</gtr:id><gtr:title>Focal Therapy of Prostate Cancer Using Irreversible Electroporation.</gtr:title><gtr:parentPublicationTitle>Techniques in vascular and interventional radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1557-9808</gtr:issn><gtr:outcomeId>5915dc838a5734.95736611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DD0C64F-2449-4273-AF1D-944E2F0AC236</gtr:id><gtr:title>Focal therapy for prostate cancer: opportunities and uncertainties.</gtr:title><gtr:parentPublicationTitle>Discovery medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1539-6509</gtr:issn><gtr:outcomeId>aJpzmjvAa8J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D129CF59-5FCF-4022-B791-BC4AF4F8D9C2</gtr:id><gtr:title>A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>pm_16610_20_23774040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F69E3C7F-1046-4E3B-8AD7-EE2DEF3A6E92</gtr:id><gtr:title>General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60fa4b52210a40ffb05482104bca9ca6"><gtr:id>60fa4b52210a40ffb05482104bca9ca6</gtr:id><gtr:otherNames>Hotston MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_16610_20_23066715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB8EEA82-6CE9-4320-A5D5-9860F2946341</gtr:id><gtr:title>Time to rethink PSA screening.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f1e1f1d660632768f9a8ba1fc663d2"><gtr:id>d6f1e1f1d660632768f9a8ba1fc663d2</gtr:id><gtr:otherNames>Singh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>Wq7PvAeRF5d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81B2C1A8-4928-43DE-9035-2E9136F4533F</gtr:id><gtr:title>Focal therapy in prostate cancer: determinants of success and failure.</gtr:title><gtr:parentPublicationTitle>Journal of endourology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0892-7790</gtr:issn><gtr:outcomeId>aKwwJ3jA28j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6719FCF-4F7A-4535-8276-8416D1F14033</gtr:id><gtr:title>Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b97b4073d9043a8367a2cc592eb5578"><gtr:id>0b97b4073d9043a8367a2cc592eb5578</gtr:id><gtr:otherNames>Abd-Alazeez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>pm_16610_20_24126797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C0B9242-CCDB-46FC-B649-1DE2C52F3EA1</gtr:id><gtr:title>Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>pm_16610_20_24121817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C02DDA3A-E167-48B0-A7A6-15AA01A9B8AE</gtr:id><gtr:title>A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis.</gtr:title><gtr:parentPublicationTitle>Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e64086c13298f0f40dd2cd22f6155ee7"><gtr:id>e64086c13298f0f40dd2cd22f6155ee7</gtr:id><gtr:otherNames>Dikaios N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0895-6111</gtr:issn><gtr:outcomeId>5915dad9142c89.79146409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5608876-425D-4803-9C35-7CE74F1688C6</gtr:id><gtr:title>Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for cytometry in tumours magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Investigative radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e7224a737e5ef6230d0dba2a9221bf"><gtr:id>50e7224a737e5ef6230d0dba2a9221bf</gtr:id><gtr:otherNames>Panagiotaki E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0020-9996</gtr:issn><gtr:outcomeId>5675dd14024ad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99393057-A647-4A27-8923-848926A52CC3</gtr:id><gtr:title>Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>Brachytherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a447763738280388783e60c367254aa"><gtr:id>3a447763738280388783e60c367254aa</gtr:id><gtr:otherNames>Peters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1538-4721</gtr:issn><gtr:outcomeId>5915db798add12.49271577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F082A5F7-BE11-47BA-94F1-037994A0B265</gtr:id><gtr:title>INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c6afdb94b8a082f9ac2e93d98bdca44"><gtr:id>9c6afdb94b8a082f9ac2e93d98bdca44</gtr:id><gtr:otherNames>Johnston E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>5915dada51edd3.42472859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD547A03-A377-4639-8577-1B5263659C4B</gtr:id><gtr:title>Words of Wisdom. Re: Multiparametric Magnetic Resonance Imaging (MRI) and Subsequent MRI/Ultrasonography Fusion-guided Biopsy Increase the Detection of Anteriorly Located Prostate Cancers.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cf8e672313859e3fe207a1c17e10b94"><gtr:id>9cf8e672313859e3fe207a1c17e10b94</gtr:id><gtr:otherNames>Dinneen E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915dc850f3a45.60876559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480A8FA6-1438-47AF-B4A1-7539F0AA1E8E</gtr:id><gtr:title>Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef5d9a864988a15b77d53d4762c71fc3"><gtr:id>ef5d9a864988a15b77d53d4762c71fc3</gtr:id><gtr:otherNames>Robertson NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_16610_20_23312572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B40DEEBC-AAA7-44B5-AF45-6D86C6EB2B31</gtr:id><gtr:title>Testicular and paratesticular tumours in the prepubertal population.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>UCUnvWxWzdg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA1C496C-FC64-4B0D-BA7D-BBC93D5EA93B</gtr:id><gtr:title>Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>83B00556DC9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>223F7654-E1B7-4005-8CD1-3D3DE54D4F28</gtr:id><gtr:title>A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6454855c445b6fbb286e933cb83c3172"><gtr:id>6454855c445b6fbb286e933cb83c3172</gtr:id><gtr:otherNames>Willis SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>5915dc835c5fd9.92185229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>466EEF12-C85C-42B5-9E38-3DBB68EDFDC4</gtr:id><gtr:title>Complications After Systematic, Random, and Image-guided Prostate Biopsy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31b313caac842838f1bd9b83c302b8ab"><gtr:id>31b313caac842838f1bd9b83c302b8ab</gtr:id><gtr:otherNames>Borghesi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915dadb699997.74595362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50CE6E2B-1BF0-423A-94BF-6A4C75DBB32E</gtr:id><gtr:title>Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e64086c13298f0f40dd2cd22f6155ee7"><gtr:id>e64086c13298f0f40dd2cd22f6155ee7</gtr:id><gtr:otherNames>Dikaios N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>54647b64815012.38964140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A82006B-1B39-4044-AE75-6E6B2BA986E9</gtr:id><gtr:title>A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d262c39a462875461564089aa679975"><gtr:id>0d262c39a462875461564089aa679975</gtr:id><gtr:otherNames>Faure Walker NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5aa66886e40f55.16111338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00328F4F-9328-4BAA-B600-E62936F75711</gtr:id><gtr:title>The index lesion and the origin of prostate cancer.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>9D559409ADE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDBC4952-E59F-4A3D-ADF1-2D97D93D5A16</gtr:id><gtr:title>&amp;quot;Textural analysis of multiparametric MRI detects transition zone prostate cancer&amp;quot;.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9c2a439a092c7f1c14e4d1e537110f"><gtr:id>1a9c2a439a092c7f1c14e4d1e537110f</gtr:id><gtr:otherNames>Sidhu HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>5915dadb1059b6.51538161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AAD54E7-B8C1-4BDA-941E-3952A13E118D</gtr:id><gtr:title>Part I: Primary malignant non-Wilms' renal tumours in children.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>DE1E0DC88F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F93AECB0-F0D6-42C5-89CC-C0C0A5F1D498</gtr:id><gtr:title>Molecular prognostic factors in penile cancer.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/944aadb6fc603d7c330dff538c389560"><gtr:id>944aadb6fc603d7c330dff538c389560</gtr:id><gtr:otherNames>Muneer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>42699BA5577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5034801-67A9-40FB-99F9-D6A215613DB8</gtr:id><gtr:title>Nonmyeloablative allogeneic stem-cell transplantation for metastatic renal cell cancer: a review and update.</gtr:title><gtr:parentPublicationTitle>TheScientificWorldJournal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8efac13a7cedb37072f2b59590e847ec"><gtr:id>8efac13a7cedb37072f2b59590e847ec</gtr:id><gtr:otherNames>Erotocritou P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1537-744X</gtr:issn><gtr:outcomeId>EE98BBEBE8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6667208-6D09-4BD2-AF78-070E4AB3A412</gtr:id><gtr:title>Endoscopic ablation: Irreversible tide of technological advancement?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>9D41C3BE771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E36B95E-B5B8-4D8A-B0F8-61D979007160</gtr:id><gtr:title>Transperineal Magnetic Resonance Imaging-targeted Biopsy versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-recurrent Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5915db7908ed42.75158790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DA47292-2CA8-4505-A6B6-59A68FEF8576</gtr:id><gtr:title>Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>C84079B4402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF09502F-BE25-4FCE-A82D-4DFEA4FF9AA8</gtr:id><gtr:title>A statistical motion model based on biomechanical simulations for data fusion during image-guided prostate interventions.</gtr:title><gtr:parentPublicationTitle>Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>6A57EDA6E78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B9C8C9B-F474-4C40-8D8D-F0C8CF540396</gtr:id><gtr:title>Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e6ac64dbe5fccc55fa9f0e78ece85df"><gtr:id>0e6ac64dbe5fccc55fa9f0e78ece85df</gtr:id><gtr:otherNames>Barzell WE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_22818143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF659F0F-E1B5-4A48-87C5-066ED2134B73</gtr:id><gtr:title>[Focal therapy for prostate cancer: German version].</gtr:title><gtr:parentPublicationTitle>Der Urologe. Ausg. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4bae62be7efeeedfdabbacb589902f"><gtr:id>ff4bae62be7efeeedfdabbacb589902f</gtr:id><gtr:otherNames>Kasivisvanathan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-2592</gtr:issn><gtr:outcomeId>5915dc856bf712.74288998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30B65D5F-A73F-49CE-937C-0AAD94883F69</gtr:id><gtr:title>A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>54647b63b9cbb3.62122903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F83C9A7-2CBC-4C86-855F-C749BFFC356E</gtr:id><gtr:title>Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e64086c13298f0f40dd2cd22f6155ee7"><gtr:id>e64086c13298f0f40dd2cd22f6155ee7</gtr:id><gtr:otherNames>Dikaios N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>5915dc85d787a4.58919498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08DD3245-A135-41DA-B690-4B9CF255AA83</gtr:id><gtr:title>Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome.</gtr:title><gtr:parentPublicationTitle>The Urologic clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5437d6761080fc3dc7bb45ee999a78"><gtr:id>2f5437d6761080fc3dc7bb45ee999a78</gtr:id><gtr:otherNames>Edison E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0094-0143</gtr:issn><gtr:outcomeId>5aa66887837cc8.47392370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEEE9D1C-2148-423F-B7CC-590714BEB675</gtr:id><gtr:title>Re: Tumor target volume for focal therapy of prostate cancer--does multiparametric magnetic resonance imaging allow for a reliable estimation?: F. Cornud, G. Khoury, N. Bouazza, F. Beuvon, M. Peyromaure, T. Flam, M. Zerbib, P. Legmann and N. B. Delongchamps. J Urol 2014; 191: 1272-1279.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>54647b63467eb3.60152480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>338F45F3-8B59-4C6A-B09B-278E6ADE626A</gtr:id><gtr:title>Is focal therapy the future for prostate cancer?</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>GP4p4S7vw9t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F2A8EB-8A8A-4E56-AA7A-4BD895AF9FEB</gtr:id><gtr:title>Focal therapy in prostate cancer: A review of seven common controversies.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e4e9f25a190091ba3064749126611e"><gtr:id>52e4e9f25a190091ba3064749126611e</gtr:id><gtr:otherNames>Bass EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>5915dada13e022.56908563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B556C49C-1C36-42F8-A34C-B828C31EF727</gtr:id><gtr:title>Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_16610_20_23819525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD17694D-8A49-4D92-AB45-851423E21A44</gtr:id><gtr:title>Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f419aa4318d90156b0f5d0c58c83c49d"><gtr:id>f419aa4318d90156b0f5d0c58c83c49d</gtr:id><gtr:otherNames>Berge V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>54647b60f29351.28067833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABE30CAC-1D5E-4B75-9724-E14E66325122</gtr:id><gtr:title>Urachal tumour: clinical and radiological features of a poorly understood carcinoma.</gtr:title><gtr:parentPublicationTitle>Annals of the Royal College of Surgeons of England</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd7c65ae294a10113d589e4c8ac05c8b"><gtr:id>cd7c65ae294a10113d589e4c8ac05c8b</gtr:id><gtr:otherNames>Tsiouris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0035-8843</gtr:issn><gtr:outcomeId>30E4D2552D9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB1D0BF3-D151-4B33-A525-3F3326B72F46</gtr:id><gtr:title>Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53cbc4003b7946eed1ce6c09e25a2557"><gtr:id>53cbc4003b7946eed1ce6c09e25a2557</gtr:id><gtr:otherNames>Nevoux P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_16610_20_22192756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C197BEC2-3D6A-4400-8AC4-CEF9084CEEB1</gtr:id><gtr:title>Conceptual basis for focal therapy in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of endourology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf734a82d88659fc2fc2ec3bea84ae2"><gtr:id>baf734a82d88659fc2fc2ec3bea84ae2</gtr:id><gtr:otherNames>Lecornet E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0892-7790</gtr:issn><gtr:outcomeId>Mz4MTfSPfgb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>496958C7-E573-4BAE-B51B-5794BEF54F03</gtr:id><gtr:title>Nanotechnology in the management of prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a5f2b361287817e4a21752035ec1341"><gtr:id>8a5f2b361287817e4a21752035ec1341</gtr:id><gtr:otherNames>Gommersall L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>CD4353313C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B996A07-3754-47DC-A73D-41EEB5B122EF</gtr:id><gtr:title>Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a447763738280388783e60c367254aa"><gtr:id>3a447763738280388783e60c367254aa</gtr:id><gtr:otherNames>Peters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5aa66888921d15.70067353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBE199EB-ACF5-43B7-8143-B02A430B42FD</gtr:id><gtr:title>Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6236be51faf7cb13062889b11ffeca3e"><gtr:id>6236be51faf7cb13062889b11ffeca3e</gtr:id><gtr:otherNames>Arumainayagam N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>LGt4TrcUfmx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062487B6-0643-4F1D-8362-31AA0A00E81D</gtr:id><gtr:title>Focal cryotherapy of localized prostate cancer: a systematic review of the literature.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>54647b64d05f31.27062892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EAF20E4-38EC-4DF1-867C-4D75C96618D7</gtr:id><gtr:title>Focal therapy for prostate cancer: fact or fiction?</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf734a82d88659fc2fc2ec3bea84ae2"><gtr:id>baf734a82d88659fc2fc2ec3bea84ae2</gtr:id><gtr:otherNames>Lecornet E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>Fw5ERhzwnV6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5053F383-657A-44FD-8132-3C2BE46D82C5</gtr:id><gtr:title>Re: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau and L. Lemaitre, J Urol 2006; 176: 2432-2437.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>04A610D041D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC9C4F17-0C8D-4B74-A527-2BD1B44B854A</gtr:id><gtr:title>Histological outcomes after focal high-intensity focused ultrasound and cryotherapy.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>5915dc84d2e6f6.99520486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34490583-0980-452E-868F-6755BD8CF3BC</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5915dad94666e8.51108339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CBC0B92-207B-46A1-9D10-C1BE9A9ABFFE</gtr:id><gtr:title>Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b516228537c5b627f470f3d3ae6a2a"><gtr:id>20b516228537c5b627f470f3d3ae6a2a</gtr:id><gtr:otherNames>Tay KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>5915dad857a7d4.75543185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>545AE3D6-709A-428C-942B-02913A4D7C23</gtr:id><gtr:title>Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>SgW12TXkxBF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A49305CA-025C-47C7-920E-0A3BF13EF5F6</gtr:id><gtr:title>A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_16610_20_22394583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB0267D9-2BD4-4153-A4D0-B7D92ED1B7C4</gtr:id><gtr:title>Biopsy strategies for selecting patients for focal therapy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>54647b62793892.59036409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD0E3F19-57AC-4480-B831-D68E3BD3CB04</gtr:id><gtr:title>Focal therapy for prostate cancer. Alternative treatment.</gtr:title><gtr:parentPublicationTitle>Actas urologicas espanolas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3ae8cb60b51625cac5d1fff20725d3f"><gtr:id>b3ae8cb60b51625cac5d1fff20725d3f</gtr:id><gtr:otherNames>G?mez-Veiga F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0210-4806</gtr:issn><gtr:outcomeId>54647b61e43f63.92281793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D653009B-A44F-42C0-B644-9FD626E47DAB</gtr:id><gtr:title>Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a447763738280388783e60c367254aa"><gtr:id>3a447763738280388783e60c367254aa</gtr:id><gtr:otherNames>Peters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5915db79b6ddc4.18709992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F7755DF-5E21-4646-92E8-1B2D03B25D8D</gtr:id><gtr:title>Prostate cancer recurrence after Focal Therapy: Treatment options.</gtr:title><gtr:parentPublicationTitle>Archivos espanoles de urologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1135872d8759f9cdba768c66279460a3"><gtr:id>1135872d8759f9cdba768c66279460a3</gtr:id><gtr:otherNames>Hamid S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0004-0614</gtr:issn><gtr:outcomeId>5915dadc593950.48152800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DFA7DE1-3DC8-4FFF-9C83-01F238A73CE6</gtr:id><gtr:title>Editorial comment.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_23896492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D912E8D-75F7-4B42-B6F3-F7B9AABDB8BA</gtr:id><gtr:title>Methodological considerations in assessing the utility of imaging in early prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>5915dc832e5d91.66284327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB4522D7-A86F-41D1-8AFF-B463BA5512C6</gtr:id><gtr:title>Molecular and genetic pathways in penile cancer.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0227a671ddec72737e24eaab95d189"><gtr:id>1a0227a671ddec72737e24eaab95d189</gtr:id><gtr:otherNames>Kayes O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5959ECA6307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF7ACB01-6EB3-4B1C-A0FF-4613E5945057</gtr:id><gtr:title>Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>MtvWnXJvHVP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AC0C3DC-C984-46D6-86C1-4CCF0A524107</gtr:id><gtr:title>Focal therapy for prostate cancer. Rationale, indications and selection.</gtr:title><gtr:parentPublicationTitle>Actas urologicas espanolas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3ae8cb60b51625cac5d1fff20725d3f"><gtr:id>b3ae8cb60b51625cac5d1fff20725d3f</gtr:id><gtr:otherNames>G?mez-Veiga F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0210-4806</gtr:issn><gtr:outcomeId>54647b61977d48.00353455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C07A41C-2C77-4B71-8E9B-0D853C0720C2</gtr:id><gtr:title>Prostate cancer: Melbourne consensus-noble but misguided.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>54647b624f7db6.82688064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3B80B62-88FF-4FBC-8964-60A095FBF750</gtr:id><gtr:title>Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>pm_16610_20_22328187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69E7EE20-EC67-404C-90E2-7748467B227B</gtr:id><gtr:title>Re: Limitations of Elastography Based Prostate Biopsy: J. Schiffmann, M. Grindei, Z. Tian, D.-J. Yassin, T. Steinwender, S.-R. Leyh-Bannurah, M. Randazzo, M. Kwiatkowski, P. I. Karakiewicz, P. Hammerer and L. Manka J Urol 2016;195:1731-1736.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed4ab018b6520f7507964c3c3da9d483"><gtr:id>ed4ab018b6520f7507964c3c3da9d483</gtr:id><gtr:otherNames>Grey AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>5915dada7c22f2.79988870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DF3908E-C10D-4278-B778-5A4C153F6B26</gtr:id><gtr:title>Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b97b4073d9043a8367a2cc592eb5578"><gtr:id>0b97b4073d9043a8367a2cc592eb5578</gtr:id><gtr:otherNames>Abd-Alazeez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>54647b63221f22.26818436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC27256-3D6D-409B-8E25-5F38CC237621</gtr:id><gtr:title>Defining the level of evidence for technology adoption in the localized prostate cancer pathway.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>54647b60ca8ac5.81317535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA088B84-0936-410E-9726-953742C2C634</gtr:id><gtr:title>The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>5915dc845eb3f6.97449758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062560DC-68A3-4790-A323-BEFABE07C8D7</gtr:id><gtr:title>Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>5aa668890850a3.59005584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29BC624E-F1A6-4D31-AE06-99398A605059</gtr:id><gtr:title>Active surveillance: is there a need for better risk stratification at the outset?</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f1e1f1d660632768f9a8ba1fc663d2"><gtr:id>d6f1e1f1d660632768f9a8ba1fc663d2</gtr:id><gtr:otherNames>Singh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>PEfjP5UiD5w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C33BC94C-61E9-4DA5-91BD-3A3176F35E7E</gtr:id><gtr:title>Nanotechnology and its relevance to the urologist.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a5f2b361287817e4a21752035ec1341"><gtr:id>8a5f2b361287817e4a21752035ec1341</gtr:id><gtr:otherNames>Gommersall L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>AFB1F2EFC13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C9F00A7-014A-4642-9F6B-4B6D19D88DF2</gtr:id><gtr:title>Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afdcf9627e5fcc00ecbbff53eb4aa093"><gtr:id>afdcf9627e5fcc00ecbbff53eb4aa093</gtr:id><gtr:otherNames>van den Bergh RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54647b61704f48.95824691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1BF74F-A9DE-44E2-8817-CAE5081B0715</gtr:id><gtr:title>The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>5915db7a693c17.71089086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A65AC979-8DFE-4ADA-83F3-A881F7AECC5C</gtr:id><gtr:title>Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>Zazde1zFzku</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AF49448-DE85-470E-9955-4FE7CF0F076B</gtr:id><gtr:title>Re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-9.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/296449e8bb3febf18015fa84adcb94bb"><gtr:id>296449e8bb3febf18015fa84adcb94bb</gtr:id><gtr:otherNames>Shanmugabavan Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54647b645d8227.09333556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A202BA96-2365-4B49-8A23-FDE2B798320D</gtr:id><gtr:title>MR to ultrasound registration for image-guided prostate interventions.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>UJCJnvVyvdi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48A62CDC-5E02-4E05-A363-13E1A8C84F0B</gtr:id><gtr:title>Life after prostate cancer. Time to evaluate focal therapy.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38c30afccfa06474c87a8387aad0fc97"><gtr:id>38c30afccfa06474c87a8387aad0fc97</gtr:id><gtr:otherNames>Cathcart P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>mFmDCSVHfbM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F7D9486-DA4B-4CCA-8A9C-1FBE2AE6956E</gtr:id><gtr:title>Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe5e9c2c85f1431b1dc66f938326d3eb"><gtr:id>fe5e9c2c85f1431b1dc66f938326d3eb</gtr:id><gtr:otherNames>Donaldson IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54647b64a74626.31246685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38437459-8332-4539-B54A-8136DE7FC309</gtr:id><gtr:title>Multiparametric ultrasound in the diagnosis of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b63ab154847d2ecc74557feba2ee569d"><gtr:id>b63ab154847d2ecc74557feba2ee569d</gtr:id><gtr:otherNames>Grey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>56716730582505.97420440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>823BD3CF-0053-4B79-910F-5A1ABC463243</gtr:id><gtr:title>What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7838478a8b9000e687c4618aab3f7612"><gtr:id>7838478a8b9000e687c4618aab3f7612</gtr:id><gtr:otherNames>Anastasiadis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>5915dc83f2c9b6.29429540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C7EC2FA-3393-4912-9C80-F986EF27E831</gtr:id><gtr:title>Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>54647b643874e8.92828641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FBAAA7B-3E1B-4368-99FE-1C4D5575DBD3</gtr:id><gtr:title>Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa8806e21dfc5a6757b2b2a5983fc10c"><gtr:id>fa8806e21dfc5a6757b2b2a5983fc10c</gtr:id><gtr:otherNames>van den Bos W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54647b6148e529.12403646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61F0A0BF-3A36-423D-809C-CE0E070327BD</gtr:id><gtr:title>Part II: Treatment of primary malignant non-Wilms' renal tumours in children.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>C9E3B792C11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F068344-8046-4669-853D-55B651A97561</gtr:id><gtr:title>Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study.</gtr:title><gtr:parentPublicationTitle>Urologia internationalis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/367e2351fb2e2f84d494520b1b1388ac"><gtr:id>367e2351fb2e2f84d494520b1b1388ac</gtr:id><gtr:otherNames>Rouse P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-1138</gtr:issn><gtr:outcomeId>N4uxfv9jFep</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27DD6FF7-45A9-4DFB-8A7F-16517FBCE548</gtr:id><gtr:title>Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e33068cb3fc39fd3a7d2badb577eaa0e"><gtr:id>e33068cb3fc39fd3a7d2badb577eaa0e</gtr:id><gtr:otherNames>Al-Qaisieh B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5675e3b24b762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>323E166F-B2A2-4E85-A63D-4AE194DAEE17</gtr:id><gtr:title>Re: Jarow et al.: Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop (Urology 2014;83:975-979).</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>54647b6410f016.92544059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17FFD5E2-D21E-4F7F-8690-398D81953AA3</gtr:id><gtr:title>Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/508532dab78aadda67cc07d5ce6837ac"><gtr:id>508532dab78aadda67cc07d5ce6837ac</gtr:id><gtr:otherNames>Simmons L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>AYA57T3TkG4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DB1B1D-1C3D-417E-9ACE-91B2D537FF5C</gtr:id><gtr:title>Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol 2016;69:852-3: Focal Therapy Preserves Erectile Function in Men with Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ad2d3be338e61118503281999024b4"><gtr:id>40ad2d3be338e61118503281999024b4</gtr:id><gtr:otherNames>Yap T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915db7a2dd590.20152737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E078E3B6-809D-40A5-B6AC-A35BD3DE4506</gtr:id><gtr:title>Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_16610_20_22374900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF5075C7-523A-4A28-B04C-4B0F755F9020</gtr:id><gtr:title>The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92dc41d05d95c5fcd3ffdd1616584d35"><gtr:id>92dc41d05d95c5fcd3ffdd1616584d35</gtr:id><gtr:otherNames>Rao AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>7823D10BA5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27629C0C-10AC-48AD-B006-61405B32F5E1</gtr:id><gtr:title>Prostate cancer screening and the management of clinically localized disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9cc06beb49e4879c239d1500b87f837"><gtr:id>a9cc06beb49e4879c239d1500b87f837</gtr:id><gtr:otherNames>Wilt TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_16610_20_23360718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A991F9E9-6321-4205-A7DF-724A88755B7F</gtr:id><gtr:title>The challenging landscape of medical device approval in localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>5915db79f0cda3.51739193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDCA37E6-A1F2-47BC-8067-7338EFBD4AA4</gtr:id><gtr:title>Is it time to consider a role for MRI before prostate biopsy?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>BB70BFD6357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A52195A6-9414-4D38-9256-3610DF57F0C7</gtr:id><gtr:title>Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-2872</gtr:issn><gtr:outcomeId>pm_16610_20_22852025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5805DEBF-98B3-4924-8F93-097CCC101D37</gtr:id><gtr:title>Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a5b820aca0f7a016e1bf5f26b7b0943"><gtr:id>0a5b820aca0f7a016e1bf5f26b7b0943</gtr:id><gtr:otherNames>Georgiou PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5915dad9791342.50116058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC059DA5-0035-4969-93E8-5BB6AE357DAF</gtr:id><gtr:title>Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d53b218500ae8d4b2ed732abfeb2ee1"><gtr:id>7d53b218500ae8d4b2ed732abfeb2ee1</gtr:id><gtr:otherNames>Faria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5aa66888132c59.49399551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE389F75-B9FF-4B8B-A899-CA39C2F3FA45</gtr:id><gtr:title>How will focal therapy fit in with existing treatments?</gtr:title><gtr:parentPublicationTitle>Actas urologicas espanolas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0210-4806</gtr:issn><gtr:outcomeId>54647b60a57ce8.21423984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C4CB38F-DBF5-4A58-BA78-407581D3058F</gtr:id><gtr:title>Clinical utility of transperineal template-guided mapping biopsy of the prostate after negative magnetic resonance imaging-guided transrectal biopsy.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12beb6c7cb375f761500a3e2cfbfb906"><gtr:id>12beb6c7cb375f761500a3e2cfbfb906</gtr:id><gtr:otherNames>Sivaraman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5915dc849de4e8.31271088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D82AAFC-4061-4D43-A7BA-762071416555</gtr:id><gtr:title>A novel randomised controlled trial design in prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7838478a8b9000e687c4618aab3f7612"><gtr:id>7838478a8b9000e687c4618aab3f7612</gtr:id><gtr:otherNames>Anastasiadis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54647b621ce6f7.43459930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9FDCC64-239F-4694-8C40-A747CCC38FA4</gtr:id><gtr:title>Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>5915dadad92996.96325264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AC15739-28CC-4AA9-85B3-5D7B6B28234E</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>5915dadc83c717.55400390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E22F4D52-C71C-4424-A883-073FE0B97E02</gtr:id><gtr:title>The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>162AB500267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>573D96F5-0B1A-4CBE-9DC2-90EF6DECCB00</gtr:id><gtr:title>Impact ofGa-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e09ae8e2823032f328cdfb6ce85807e"><gtr:id>0e09ae8e2823032f328cdfb6ce85807e</gtr:id><gtr:otherNames>Afaq A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5aa66888c24758.13722750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEE37482-FB60-4588-8BD9-FDF01813C7C5</gtr:id><gtr:title>The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6785e04d2dd0852067e24bd9ebce2d97"><gtr:id>6785e04d2dd0852067e24bd9ebce2d97</gtr:id><gtr:otherNames>Simmons LAM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5915dad82586d9.74041072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD788C56-E173-4A5B-94E3-732E767EED4E</gtr:id><gtr:title>The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97d1a97aa3c91f219a4cd67885bce36e"><gtr:id>97d1a97aa3c91f219a4cd67885bce36e</gtr:id><gtr:otherNames>Bott SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>p9oSi1RjGmK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6585441-38C6-461A-BA80-4887CAAFE2E9</gtr:id><gtr:title>Greenlight prostatectomy: a challenge to the gold standard? A review of KTP photoselective vaporization of the prostate.</gtr:title><gtr:parentPublicationTitle>Surgical laparoscopy, endoscopy &amp; percutaneous techniques</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1530-4515</gtr:issn><gtr:outcomeId>A75B3832298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DAFC162-E504-4268-8C9F-10AD50ED9284</gtr:id><gtr:title>The PROMIS of a New Diagnostic Pathway for Men with Suspected Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aab2a662727b6a8873ab807e91ac924"><gtr:id>5aab2a662727b6a8873ab807e91ac924</gtr:id><gtr:otherNames>Hindley RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5915dad7e96e30.50077972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2D8BD6E-C1F7-4543-BBB9-560288DC55BA</gtr:id><gtr:title>Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>5915db7acf2393.22644045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D1A617-20C9-4C72-B3FC-110836B9BBD7</gtr:id><gtr:title>Focal therapy for localized prostate cancer: a phase I/II trial.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>hq452zhyoef</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D68CE029-8DCB-4624-8149-C2981D96BBE5</gtr:id><gtr:title>Re: Jochen Walz. The &amp;quot;PROMIS&amp;quot; of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d53b218500ae8d4b2ed732abfeb2ee1"><gtr:id>7d53b218500ae8d4b2ed732abfeb2ee1</gtr:id><gtr:otherNames>Faria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5aa668867d3763.48063823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>649C4664-E7F1-462C-8A1E-C6A8661F399A</gtr:id><gtr:title>Re: Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy: M. Han, D. Chang, C. Kim, B. J. Lee, Y. Zuo, H.-J. Kim, D. Petrisor, B. Trock, A. W. Partin, R. Rodriguez, H. B. Carter, M. Allaf, J. Kim and D. Stoianovici. J Urol 2012; 188: 2404-2409.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe5e9c2c85f1431b1dc66f938326d3eb"><gtr:id>fe5e9c2c85f1431b1dc66f938326d3eb</gtr:id><gtr:otherNames>Donaldson IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_23399648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A5E83E2-EC2D-4489-A81F-28327A4DC7A6</gtr:id><gtr:title>PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>5915dc853fa449.31499828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9515E199-79C0-47D6-A69F-74AFE6D3F8F6</gtr:id><gtr:title>The metastatic cascade in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Surgical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44d74f4f818585f4ca5c70db9430266d"><gtr:id>44d74f4f818585f4ca5c70db9430266d</gtr:id><gtr:otherNames>Arya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0960-7404</gtr:issn><gtr:outcomeId>758A0BC6E7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ED3439A-B14B-49CF-8EBB-8AD3D062D503</gtr:id><gtr:title>A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations.</gtr:title><gtr:parentPublicationTitle>Progress in biophysics and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0079-6107</gtr:issn><gtr:outcomeId>bLG2YasPuXe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D62DAE2-F53A-48CE-B452-972ACFADE081</gtr:id><gtr:title>Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddc793b0b1fdfc85c1a9bb22f2ff9afe"><gtr:id>ddc793b0b1fdfc85c1a9bb22f2ff9afe</gtr:id><gtr:otherNames>Linch M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>5aa66887bae581.01214932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB3DE8B1-A188-470F-AAD4-7B64767F5395</gtr:id><gtr:title>Focal therapy will become standard treatment for localized prostate cancer: pro.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_22260743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F83FBFF-C3D2-4C30-8019-A3DAF3404CD9</gtr:id><gtr:title>Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard.</gtr:title><gtr:parentPublicationTitle>Radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6236be51faf7cb13062889b11ffeca3e"><gtr:id>6236be51faf7cb13062889b11ffeca3e</gtr:id><gtr:otherNames>Arumainayagam N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-8419</gtr:issn><gtr:outcomeId>pm_16610_20_23564713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D021C1F-0B0B-43A4-94CA-89839C06863A</gtr:id><gtr:title>Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_16610_20_23117005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FAAFA89-4FE6-40AB-903A-E8864F9B9D03</gtr:id><gtr:title>The role of focal therapy in the management of localised prostate cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_16610_20_23769825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D294EC3D-F01D-4847-BBC5-2F63327C4B52</gtr:id><gtr:title>Opening Our Eyes to Multiparametric Magnetic Resonance Imaging Before Prostate Biopsy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5915dad7ae39c8.18379553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D2BB25-C89E-4D2B-922B-9CC1CAEB04BC</gtr:id><gtr:title>The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf734a82d88659fc2fc2ec3bea84ae2"><gtr:id>baf734a82d88659fc2fc2ec3bea84ae2</gtr:id><gtr:otherNames>Lecornet E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_22819118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3371072-5881-400D-8E61-23FB75E62581</gtr:id><gtr:title>Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f1e1f1d660632768f9a8ba1fc663d2"><gtr:id>d6f1e1f1d660632768f9a8ba1fc663d2</gtr:id><gtr:otherNames>Singh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_16610_20_24207133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>354A05D7-FF5B-4B39-B631-5B360DDC9AD4</gtr:id><gtr:title>Does true Gleason pattern 3 merit its cancer descriptor?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/134fb593404f7c02f3c80ae47154f1db"><gtr:id>134fb593404f7c02f3c80ae47154f1db</gtr:id><gtr:otherNames>Miah S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>5915dadba5b9d6.06758346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FDA7865-0E21-4852-B30D-60CA23F90009</gtr:id><gtr:title>Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5aa668885356f7.07663336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140540A9-2089-44C2-A544-D0727C8A1520</gtr:id><gtr:title>Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies.</gtr:title><gtr:parentPublicationTitle>Current urology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/531e7039d4ad389e5eab2b2a88f29680"><gtr:id>531e7039d4ad389e5eab2b2a88f29680</gtr:id><gtr:otherNames>Lee DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1527-2737</gtr:issn><gtr:outcomeId>54647b6122cb46.19273533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6F931E7-6221-4D14-BDD4-D6B53DCF6636</gtr:id><gtr:title>Introduction--Targeting the lesion, not the organ.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>54647b636b8294.43910692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE0B3FD3-97E5-4ED6-B521-5C923F94159E</gtr:id><gtr:title>Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8ef7aef14bd16c82f98ffcad287088"><gtr:id>5e8ef7aef14bd16c82f98ffcad287088</gtr:id><gtr:otherNames>Uddin Ahmed H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>PWsDxJUvR1k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C870E47F-0C8E-4FA9-8710-2F460FDF6D51</gtr:id><gtr:title>What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer.</gtr:title><gtr:parentPublicationTitle>Applied health economics and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d3042787d5c6db376bae42f7a82d0da"><gtr:id>1d3042787d5c6db376bae42f7a82d0da</gtr:id><gtr:otherNames>Barbieri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1175-5652</gtr:issn><gtr:outcomeId>54647b63960406.47374505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9B7FF40-A69B-4390-A783-0A9AD44D35BE</gtr:id><gtr:title>Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ea756a7ebe6dec292e2956e7a65e941"><gtr:id>1ea756a7ebe6dec292e2956e7a65e941</gtr:id><gtr:otherNames>Langley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_16610_20_22239224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7233B861-CE13-41DB-B37A-5EC283AA91FE</gtr:id><gtr:title>3D printing in robotic assisted radical prostatectomy - an IDEAL Phase 2a study.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c58aca26abf64cb3522d5bf2a502992"><gtr:id>0c58aca26abf64cb3522d5bf2a502992</gtr:id><gtr:otherNames>Chandak P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa668862fc244.34461327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD962128-2DE6-46F0-9EF0-2C657C77005F</gtr:id><gtr:title>Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6454855c445b6fbb286e933cb83c3172"><gtr:id>6454855c445b6fbb286e933cb83c3172</gtr:id><gtr:otherNames>Willis SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>54647b62c95aa9.59942347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8681131C-4E8B-4549-AC8E-F0D83D29423D</gtr:id><gtr:title>Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4bae62be7efeeedfdabbacb589902f"><gtr:id>ff4bae62be7efeeedfdabbacb589902f</gtr:id><gtr:otherNames>Kasivisvanathan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>pm_16610_20_23063807</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58AF8DD2-DCA2-4FD7-A7C7-7BA0466E32F2</gtr:id><gtr:title>Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5915dad8d6b390.72096764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C851545D-7609-4A42-AF6E-DDEA2EC2FACE</gtr:id><gtr:title>The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2af33f149c34389d0497547d2900a22e"><gtr:id>2af33f149c34389d0497547d2900a22e</gtr:id><gtr:otherNames>Zacharakis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>8C7A22420AE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D5CFB67-F299-47C4-AF2F-81E969358E12</gtr:id><gtr:title>Systematic review of complications of prostate biopsy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d80a157fed3080fdc322892256ae55e6"><gtr:id>d80a157fed3080fdc322892256ae55e6</gtr:id><gtr:otherNames>Loeb S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_16610_20_23787356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>302A974E-82FD-4C1A-8B3F-C18883F3427A</gtr:id><gtr:title>Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment.</gtr:title><gtr:parentPublicationTitle>Archivos espanoles de urologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf734a82d88659fc2fc2ec3bea84ae2"><gtr:id>baf734a82d88659fc2fc2ec3bea84ae2</gtr:id><gtr:otherNames>Lecornet E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0004-0614</gtr:issn><gtr:outcomeId>puNU14FbmAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CD3B4B3-735E-417E-8510-243F54F0184A</gtr:id><gtr:title>Photodynamic therapy for focal ablation of the prostate.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6236be51faf7cb13062889b11ffeca3e"><gtr:id>6236be51faf7cb13062889b11ffeca3e</gtr:id><gtr:otherNames>Arumainayagam N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>eHgX3jjJcaT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>553F3B76-B519-406D-BDB5-274A453756EC</gtr:id><gtr:title>Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.</gtr:title><gtr:parentPublicationTitle>Surgical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-7404</gtr:issn><gtr:outcomeId>610BFDCE05E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6951D155-F3C6-4F04-AA2D-98A11EF05CD9</gtr:id><gtr:title>Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventions.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb4ee58dc98e756ab9f3b92d2a77c803"><gtr:id>fb4ee58dc98e756ab9f3b92d2a77c803</gtr:id><gtr:otherNames>Bonmati E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5aa66886b2f457.99595879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E17EA187-D45B-4D71-AE42-B81D21669DE1</gtr:id><gtr:title>Health technology assessment in evolution - focal therapy in localised prostate cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>54647b62ee2543.26065348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C9F1822-6B91-4F4B-BD5E-836D33BEEB2E</gtr:id><gtr:title>Tumor focality in prostate cancer: implications for focal therapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeae2df167f8e0ddbe7b3de242640ad"><gtr:id>fbeae2df167f8e0ddbe7b3de242640ad</gtr:id><gtr:otherNames>Karavitakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>Nio7LLu54qj</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002509</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>